Corporate Presentation April 2019 TSXV | NHP - A GROWTH STORY - - PowerPoint PPT Presentation

Corporate Presentation

April 2019 TSXV | NHP

> Mondias Natural Products (TSXV: NHP) specializes in the commercialization and development of evidence-based botanical products for the bio-agriculture and healthcare markets. > Mondias is focused on large, growing markets, such as the biopesticides, biostimulants, sleeping aids, wound healing, acne, nail fungus, and hair loss markets. > The Company has a strong IP portfolio, including 53 products with Health Canada Natural Product Numbers (NPNs) and 4 patents. > Mondias generates revenues by selling its products through its Holizen division and web platform (www.holizen.com), as well as through retailers, distributors, and co-branding partnerships.

• A GROWTH STORY

2

Biopesticides Biostimulants Global annual economic losses of $10 billion to $100 billion from grey mould and powdery mildew postharvest infections Sleeping aids Global sleeping aids market valued at $69.5 billion in 2017, expected to reach $101.9 billion by 2023

2020

Insect repellent Global insect repellent market expected to grow at a CAGR of 6.5% to reach $7 billion by 2026 Acne Global acne drug market expected to grow at a CAGR of 4.2% to reach $5.9 billion by 2025 Nail fungus Global nail fungus market expected to grow at a CAGR of 7.6% to reach $6.7 billion by 2026 Wound healing Global wound healing market valued at $23.3 billion in 2016, expected to reach $35 billion by 2025 Hair loss Global hair loss market valued at $7.3 billion in 2015, expected to reach $11.8 billion by 2024

FOCUS ON LARGE, GROWING MARKETS

2019

3

Jean-Philippe Gravel, MBA President and Chief Executive Officer

Over 14 years of experience in business management and development, having held strategic roles in the medical, pharmaceutical and banking industries.

Jamil Samsatly, M.Sc. Chief Scientific Officer

Completing his Ph.D. at McGill University. Over 10 years of experience in sustainable agriculture, healthy agri-food systems and molecular biotechnology.

Sabino Di Paola, CPA, CA Chief Financial Officer

Over 10 years of experience in audit, finance and accounting as an auditor for PricewaterhouseCoopers and BDO Canada.

• L. Derek Lindsay, MBA

Vice President, Corporate Development

Expertise in raising equity and financing projects, structuring creative strategic partnerships, increasing investor awareness and completing acquisitions.

André Rancourt Chairman and Co-founder of Mondias

(previously CEO and Chairman for Tetra Biopharma)

Louis Doyle Executive Director of Quebec Bourse

(previously VP of TSX Venture Exchange, Montreal)

Frank Palantoni CEO of LabM2

(previously President of Pet and Life Science, Global CEO of Gerber Products and CEO of Novartis Consumer Health)

Michel Timperio President - Cannabis Business, Neptune Wellness Solutions

(also on the board of Relevium Technologies)

Bertrand Venne Consultant

(previously President and CEO of Les Entreprises Pâtes et Croûtes and Aliments Novali)

BOARD OF DIRECTORS

LEADERSHIP

• Broad expertise in

natural products development and commercialization

• 4

> The biopesticide market represents less than 5% of the global pesticide market, which is expected to grow to $90 billion by 2023. > Synthetic pesticides pollute ecosystems, cause human health problems (recent example of Glyphosate or Roundup) and create pest resistance. > As a result, there is an increased number of growers that are seeking eco-friendly alternatives to pesticides.

* Source: L. Hua et al., 2018

A BETTER ALTERNATIVE TO SYNTHETIC PESTICIDES?

• Biopesticides

Biostimulants +$10 billion market

• pportunity*
• 5

> CELEXT07 bio-defense stimulant proven to be a superior,

eco-friendly alternative to synthetic fungicides.

> Developed to prevent and fight diseases affecting crops,

such as grey mould (viticulture, vegetables) and powdery mildew (cannabis).

> Successful large-scale greenhouse trials on tomatoes, lettuce and hops. > Positive field tests on cannabis leaves with leading cannabis producer. > Patent pending on herbal phytosanitary composition and methods for the prevention and

treatment of plant infections in Canada, the U.S., Europe, China, Australia, Brazil and WIPO.

CELEXT07 BOTANICAL EXTRACT

• Superior

eco-friendly alternative to synthetic fungicides

• 6

NEXT STEPS

> Product is ready to market. > Ongoing product testing and discussions

with leading cannabis producers, as well as agriculture and horticulture companies.

> Strategy to develop co-branding

partnerships.

> Production capacity secured to meet

demand from potential clients.

• CELEXT07
• Product ready

to market!

• 7

SLEEP PROBLEMS ARE:

> Associated with accidents and human

errors (10-15% of fatal motor-vehicle crashes and large number of medical errors).

> Common (insomnia and sleep apnea). > Likely to increase (24/7 society).

ANXIETY AND DEPRESSIVE DISORDERS ARE:

> The two most common psychiatric

illnesses across the globe.

> The main causes of sleep deprivation.

* Source: P&S Market Research, May 2018, and IndustryARC, April 2018

• SLEEP DEPRIVATION

AND ANXIETY: A GROWING PROBLEM

• Combined

+$100 billion sleeping aid and anxiety market by 2023*

• 8

> Mondias developed its first natural health product line with

proven efficacy for sleep and anxiety disorders. Ongoing research to assess if our product can induce restorative sleep in patients suffering from chronic pain.

> Patent pending on herbal compositions for the treatment of

sleep and dream‐related disorders in the U.S. and WIPO. NEXT STEP Web-based launch of our new product line planned for the second half of 2019.

* Source: P&S Market Research, May 2018

SLEEPING AID PRODUCT LINE

• Proven efficacy

for sleep and anxiety disorders

• 9

> Mondias generates revenues by selling

its products through natural health product stores via its Holizen division.

> Goal to expand the business in the rest

• f Canada and grow sales in Quebec by

stepping up promotional activities.

> Sales representation agreement signed

with Wisdom of Nature Inc., a company specializing in retail sales of natural health products in Ontario.

> Ontario has 450 natural health

products stores, compared to just over 200 in Quebec.

> Next step includes expansion into

Western Canada.

* Source: P&S Market Research, May 2018

HOLIZEN

• 2019 expansion

could triple market size

• 10

> Revenues of $536,659 for the year ended November 30, 2018 (no comparative figure as F2017 consisted of a single quarter). > Q4 2018 revenues increased 11.4% to $157,369 from $141,253 in Q4 2017. > Gross margin of xx.x% in Q4 2018 versus 45.5% in Q4 2017. > As at November 30, 2018, working capital of $796,559, including a cash balance of $1,115,020. > Low-cost structure, with a projected burn rate of $115,000 per quarter.

Je vais produire un tableau

F2018 FINANCIAL PERFORMANCE

• Gross margin of

xx.x% in Q4 2018

• 11

Mondias has 53 Natural Product Numbers (NPNs) registered with Health Canada in various health market segments. It has commercialized approximately 30 products in the following market segments:

* Source: P&S Market Research, May 2018

• Goal is to bring

these products to market in the next three years

• NATURAL

PRODUCTS PIPELINE

> Bone health > Stress and anxiety > Cardiovascular health > Hair health > Pain management > Skin health > Joint pain > Digestive health > Energy and vitality

12

> CELEXT07: form co-branding partnerships with leaders in the

agriculture, horticulture and cannabis markets.

> Sleeping aid product line: web-based launch planned in the second

half of 2019.

> Looking at complementary acquisitions to boost revenues and

product offering.

> Expand Holizen’s operations in Ontario and Western Canada. > Continue to develop other products with the goal of bringing them

to market.

GROWTH STRATEGY

• Focus is on

lead products and short-term growth

• pportunities
• 13

On November 26, 2018, Mondias completed a reverse takeover of Element 79 Capital Inc. that resulted in the following:

Mondias shareholders Element 79 shareholders Private placement 41,882,760 8,008,044 13,245,000 Shares outstanding 63,135,805 Warrants (exercice price: $0.25) 6,882,760 Options (average exercice price: $0.xx) 2,950,402 Fully diluted shares 72,968,967 Escrowed shares 35,000,001 Insider ownership 36,333,334 (58%)

CAPITALIZATION

• Committed

insiders hold 58% of the shares

• 14

FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements that reflect the Company’s current expectations regarding future events. There’s a risk that expectations, and the forward-looking statements on which they are based, will not prove to be accurate.

Readers are cautioned not to place undue reliance on forward-looking statements, as they involve risks and uncertainties that could make actual results differ materially from those projected therein and depend on a number of factors, including, but not limited to, the Company’s lack of history of profitability, the availability of future financing, the Company’s ability to protect its intellectual property rights and obtain patents, dependence on key personnel, the competitiveness of the marketplace, technological obsolescence, share price volatility and other risks described from time to time in the Company’s filings. While Mondias acknowledges that future events and developments may cause its views to change, it undertakes no obligation to update forward-looking statements, except as required by applicable securities laws.

15

• CONTACT

INFORMATION

Jean-Philippe Gravel

Chief Executive Officer

• 1 866-722-2442

jpgravel@mondias.ca

16